Interpace Biosciences presents two posters at ATA meeting

Interpace Biosciences (IDXG) presented two new scientific posters at the 2025 American Thyroid Association Annual Meeting. The first poster, “Utilizing Archival Cytology Slides to Overcome Molecular Testing Insufficiency Rates in Cytologically Indeterminate Thyroid Nodules: An Institutional Experience”, led by Temma Kaufman, MD, described a hospital-system-wide quality-improvement effort. Among 65 thyroid FNA cases previously deemed insufficient for another testing platform, 56 yielded successful molecular results using Interpace’s ThyGeNEXT + ThyraMIRv2 testing from archival cytology slides-supporting fewer repeat FNAs and streamlined workflows. The second poster, “Refined Risk Stratification of Bethesda III/IV Thyroid Nodules Using ThyGeNEXT and ThyraMIRv2” reported outcomes from 28,144 indeterminate nodules tested between September 2022 and April 2025. ThyGeNEXT identified BRAF V600E-like alterations in ~4%-6% and RAS-like alterations in ~19%, while 76%-77% were mutation-negative. Subsequent ThyraMIRv2 microRNA profiling further stratified malignancy risk within both RAS-like and mutation-negative groups, enabling more precise clinical decision-making. “These data continue to validate the real-world utility of our combination platform,” said Tom Burnell, CEO “The independent institutional experience highlights practical advantages-like testing from archival cytology slides-that can reduce repeat procedures, while our 28,000-plus case analysis demonstrates how integrating DNA mutations with microRNA expression refines risk where clinicians need it most.”